The study used multigene sequencing to identify genomic alterations in patients with metastatic breast cancer. Patients with genomic alterations ranked as ESCAT I/II saw improved progression-free survival with targeted therapies matched to their genomic changes, while those without these alterations did not benefit from the treatment.
Researchers used next-generation DNA sequencing to detect residual disease in patients treated with CAR-T therapy for acute lymphoblastic leukemia. The study found that DNA sequencing was more sensitive and accurate than flow cytometry in predicting relapse, enabling earlier intervention.
The AACR and Pelotonia launch a grants program to recognize five influential female researchers in breast and gynecologic cancers. Nomination deadlines are January 14, 2022, with awards presented at the AACR Annual Meeting 2022.
A fasting-mimicking diet was found to be safe and biologically active in cancer patients, with potential benefits for modulation of metabolism and enhancement of antitumor immunity. The study demonstrated significant reductions in blood glucose and growth factor concentrations, as well as enhancements in intratumor T-cell infiltration.
Patients with advanced renal cell carcinoma treated with checkpoint inhibitor combination nivolumab plus ipilimumab experienced longer treatment-free survival compared to those receiving targeted therapy sunitinib. The analysis revealed significant differences in how patients spent their overall survival time between the two treatments.
A study found that younger B-cell non-Hodgkin lymphoma survivors are at a higher risk of developing age-related diseases, including renal failure, pneumonia, and nutritional deficiencies. The research suggests that aggressive treatment regimens may be the underlying factor contributing to this increased risk.
The American Association for Cancer Research (AACR) has introduced two career development awards to support underrepresented minority scientists in cancer research. The awards, valued at $300,000 and $375,000 over three years, aim to promote diversity, equity, and inclusion in the field.
Researchers found that combining an Aurora Kinase A inhibitor with a KRAS inhibitor or WEE1 inhibitor showed efficacy against lung cancer cells resistant to KRAS inhibition. The study suggests that Aurora Kinase A activation contributes to intrinsic and acquired resistance to sotorasib in KRAS-mutated lung cancer cells.
A phase Ib study found that combining sotorasib, a KRAS G12C inhibitor, with afatinib, a pan-ErbB tyrosine kinase inhibitor, showed antitumor activity in patients with KRAS-mutant non-small cell lung cancer. The combination demonstrated a high disease control rate and improved efficacy compared to prior therapies.
A phase II clinical trial has shown that the DNA alkylation drug DM-CHOC-PEN improved survival in adolescent and young adult patients with central nervous system cancers. The treatment was well-tolerated, with no severe toxicities observed, and showed potential for combination with other treatments.
A peptide-drug conjugate called CBX-12 has been shown to enhance the efficacy of immune checkpoint inhibitors in preclinical cancer models by targeting the acidic environment of cancer cells. The treatment exhibited significantly delayed tumor growth, improved survival, and complete tumor regressions compared to immunotherapy alone.
A recent study found that non-Hispanic Black patients who received immunotherapy for advanced-stage non-small cell lung cancer had a lower risk of death compared to non-Hispanic white patients. The researchers controlled for access-related issues and found disparities persisted in certain populations.
A study found that chronic stress, measured by allostatic load, was associated with a lower likelihood of completing chemotherapy and lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer. Allostatic load may be a better predictor than genetic ancestry for chemothe...
A pilot program providing tailored cervical cancer screening for trans men and nonbinary people was well-received, with 100% satisfaction rates. The program aimed to address barriers such as dysphoria and stigma, and could serve as a model for similar programs.
The ARAMIS phase III clinical trial found that darolutamide improved metastasis-free survival and overall survival in Black/African American patients. Darolutamide-treated patients had a higher three-year overall survival rate and longer time to disease progression compared to placebo-treated patients.
A simulated screening process for a pancreatic cancer clinical trial showed that Black patients were significantly more likely than white patients to be excluded from trials. The study found that nutrition and infectious disease criteria disproportionately excluded Black patients, while a history of prior cancer treatment excluded more...
A recent study found that HPV vaccine hesitancy has either stabilized or increased in some ethnic and age groups, highlighting the need for targeted campaigns to encourage hesitant families. The study also identified several reasons why parents hesitate to vaccinate their children with the HPV vaccine.
A recent study has identified significant disparities in nasopharyngeal cancer incidence among Asian American ethnic subgroups. Chinese and Laotian Americans were found to have the highest incidence rates, with rates surpassing other Asian American subgroups.
A predictive model estimated that cervical cancer may be eliminated in the US by 2030 in low-poverty areas, but not until 2044 in high-poverty areas. Health care disparities are a major contributor to these disparities, including lower vaccination rates and higher prevalence of cancer-causing HPV types.
Patients with relapsed metastatic melanoma who received prior anti-PD-1 therapies had a lower response rate to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL). ACT-TIL was less effective in these patients compared to those who had never received anti-PD-1 therapy. The study found that the objective response rate and ...
A phase II clinical trial of remetinostat gel found a 69.7% response rate to the topical treatment, with complete responses observed across multiple BCC subtypes, and a durable response in nodular BCCs.
Researchers created a new indicator, CPRS, to measure overall cancer risk based on an individual's unique combination of DNA changes. A healthy lifestyle is associated with decreased cancer incidence in people with a high genetic risk.
The investigational therapy ficlatuzumab, targeting the extracellular hepatocyte growth factor (HGF), showed clinical efficacy in patients with relapsed/refractory acute myeloid leukemia. A 53% complete response rate was observed, with improved progression-free and overall survival rates.
Breast cancer mortality rates have decreased among Black and Hispanic women since 1990, narrowing the gap with white women. However, Black women still experience double the mortality rates of non-Hispanic white women.
Patients enrolled in the US military's universal health care system experienced improved colon cancer survival rates compared to those in the general population. The study found a 26% lower risk of death among Black patients, highlighting the positive impact of universal healthcare on racial disparities in cancer outcomes.
A recent study found a direct molecular link between red meat consumption and colorectal cancer development, revealing genetic mutations indicative of DNA damage. High red meat intake was associated with increased cancer-related mortality and poorer patient survival.
In a survey of 1,062 adults aged 45-75, most preferred fecal immunochemical tests (FIT/FOBT) or multitarget stool DNA (mt-sDNA) over colonoscopy. The preference for mt-sDNA was higher among younger age groups and non-Hispanic white individuals, while older adults and minority groups preferred colonoscopy.
Research reveals associations between circulating tumor cell (CTC) mutations and clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC). The study identified novel genetic alterations linked to response to AR inhibitors, including gains of ATM, NCOR2, and HSD17B4, which were associated with sensitivity to treatment.
A machine learning-based model predicts the probability of lung cancer among patients with multiple pulmonary nodules, achieving high accuracy in validation cohorts. The PKU-M model also surpasses prior logistic regression-based models and a previously established AI tool in diagnosis.
A meta-analysis of breast cancer survivors found they are less likely to get pregnant due to higher risks of complications. However, when they do conceive, most deliver healthy babies with no adverse effects on their long-term survival or overall health.
A study found that under-recognition of symptoms is common among breast cancer patients receiving radiation, with younger patients and Black patients being more likely to experience this. The researchers identified several factors associated with symptom under-recognition, including age, race, and treatment regimen.
A new clinical trial suggests that postmenopausal patients with hormone receptor-positive and HER2-negative breast cancer and a low recurrence score of 25 or lower may safely avoid chemotherapy. In contrast, premenopausal patients who receive chemotherapy show improved invasive disease-free survival and overall survival rates.
For older patients with hormone receptor-positive breast cancer, omitting postoperative radiation therapy did not compromise survival or increase risk of distant metastasis. Local recurrence rates were higher in those who didn't receive radiation therapy.
A meta-analysis found that circulating tumor cell dynamics were associated with overall survival in patients with metastatic breast cancer. Changes in CTC levels before and after treatment were linked to prognosis, with median overall survival greatest for those who remained CTC-negative.
Extended follow-up data from the monarchE trial shows that abemaciclib continues to improve IDFS among high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer patients. The addition of abemaciclib to standard adjuvant endocrine therapy reduces the risk of invasive disease by 25 percent.
Women who receive mastectomy and reconstructive surgery are at increased risk of developing persistent use of opioids and sedative-hypnotic drugs. The study found that 13.1% of patients become new persistent opioid users after surgery, while 6.6% develop persistent sedative-hypnotic use.
Researchers found that concurrent dexamethasone administration with an immune checkpoint inhibitor reduced survival in both immunosensitive and immunoresistant mouse models. In human patients, those taking dexamethasone at baseline had significantly worse overall survival compared to non-users.
A computational method combining clinicodemographic variables and deep learning of pre-treatment histology images accurately predicts response to immune checkpoint blockade. The model, validated in an independent cohort, achieves high accuracy and can stratify patients into high versus low risk for disease progression.
A study published in Cancer Discovery found that patients with advanced-stage lung cancer had greater enrichment of oral commensals in the lung than those with early-stage disease, leading to decreased survival. The presence of specific bacteria was associated with tumor progression and activation of inflammatory pathways.
Research reveals that African American men's prostate cancer tumors have higher frequencies of certain genetic alterations compared to white men. These alterations may contribute to more aggressive disease and higher mortality rates among Black men.
Younger patients with resected melanoma showed a benefit from adjuvant bevacizumab treatment, while older patients did not. The study suggests that sFRP2 may promote angiogenesis in older patients with melanoma, which is superseding the role of VEGF.
Baseline ctDNA levels predicted responses to first-line immune checkpoint inhibition in patients with melanoma, but not second-line treatment. Low ctDNA levels associated with longer progression-free survival in both discovery and validation cohorts.
In a phase I clinical trial, vorinostat in combination with sirolimus or everolimus demonstrated improved outcomes for patients with heavily pretreated relapsed/refractory Hodgkin lymphoma. The treatment combination achieved an objective response rate of 55% and median progression-free survival of 5.3 months.
A new urine-based liquid biopsy test, UroCAD, has been developed to detect bladder cancer with higher sensitivity and similar specificity compared to traditional urine cytology. The test analyzes DNA copy number variants in urine exfoliated cells and shows promise for reducing the frequency of cystoscopy examinations.
A study found that using proton pump inhibitors (PPIs) worsened survival rates and disease progression in patients with urothelial cancer treated with atezolizumab. PPI use did not affect overall survival or response to chemotherapy.
Patients with germline or somatic mutations in DNA repair genes showed better clinical outcomes after platinum-based chemotherapy. These mutations were found in genes such as BRCA1, BRCA2, and PALB2, which are involved in a form of DNA repair known as homologous recombination.
A phase II trial shows that combining intratumoral IL-12 electroporation with pembrolizumab increases immune cell infiltration and induces clinical responses in patients with unresectable or metastatic melanoma, even in those with immunologically quiescent tumors.
A study found that patients experienced higher rates of infections in the years leading up to a cancer diagnosis compared to those without cancer. The researchers discovered an association between specific infections and increased risk of certain types of cancer.
A new imaging technique combining high-resolution imaging with quantitative measurement of tissue elasticity can detect cancer within resected margins of breast-conserving surgery. The study found QME to have high sensitivity and specificity for detecting cancer, reducing the need for additional surgeries.
A new study published in Cancer Research found that Indigenous American ancestry is associated with a greater incidence of HER2-positive breast cancer in Latinas. The study analyzed data from over 1,300 patients and found that women with higher proportions of IA ancestry were more likely to develop HER2-positive tumors.